Table 3 Outcome of 95 episodes of streptococcal prosthetic joint infections; univariate analysis
Variables | Remission (n = 67) | Failure (n = 28) | p |
|---|---|---|---|
Age > 70 years | 35 (36.8 %) | 11 (39.3 %) | .25 |
≥1 comorbidity | 46 (68.7 %) | 24 (85.7 %) | .09 |
Total hip arthroplasty | 40 (42.1 %) | 10 (35.7 %) | .03 |
Type of infection (early/delayed/late) | 20 (29.8 %)/18 (26.9 %)/29 (43.3 %) | 11 (39.3 %)/7 (25 %)/10 (35.7 %) | .19 |
Fever | 35 (36.8 %) | 17 (60.7 %) | .45 |
CRP in mg/L, mean value ± SD | 154.6 ± 121.9 | 207.2 ± 148.3 | .09 |
S. agalactiae (group B streptococci) | 27 (28.4 %) | 10 (35.7 %) | .68 |
Antibiotic treatment prior to admission | 18 (18.9 %) | 8 (28.6 %) | .86 |
Sinus tract | 15 (15.8 %) | 3 (10.7 %) | .18 |
Concomitant bacteremia at the time of diagnosis | 11 (16.4 %) | 8 (28.6 %) | .18 |
DAIR | 32 (33.7 %) | 23 (82.1 %) | .002 |
Primary arthroplasty | 53 (79.1 %) | 20 (71.4 %) | .42 |
Hematogenous origin | 10 (14.9 %) | 8 (28.6 %) | .12 |
Rifampicin based combinations | 44 (46.3 %) | 8 (28.6 %) | .001 |
Rifampicin + levofloxacin | 24 (25.2 %) | 4 (14.3 %) | .04 |